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Background: A novel brain drug delivery system using cationic bovine serum albumin 
(CBSA)-conjugated biodegradable polymersomes (CBSA-PO) was prepared, and its intracel-
lular delivery mechanism and brain delivery kinetics were evaluated.
Methods and results: Biodegradable poly(ethylene glycol)-poly(ε-caprolactone) (PEG-PCL) 
was used to prepare the polymersomes, and thiolated CBSA was conjugated with the surface of 
the polymersome. Transmission electron microscopy and dynamic light scattering showed that the 
CBSA-PO had a round and vesicle-like shape, with a mean diameter of around 100 nm. Coupling 
of CBSA with polymersomes was confirmed by X-ray photoelectron spectroscopy. Uptake of 
CBSA-PO by bEnd.3 cells was significantly higher than that of unconjugated polymersomes, but 
was inhibited by low temperature, free CBSA, and poly-L-lysine, indicating that endocytosis was 
energy-driven and absorptive-mediated. Cell viability assays confirmed the good safety profile 
of biodegradable CBSA-PO. Pharmacokinetic results demonstrated that the polymersomes had 
long circulation times, and CBSA conjugation on the polymersomes significantly increased the 
blood–brain barrier permeability surface area product by 3.6-fold and the percentage of injected 
dose per gram brain (% ID/g brain) by 2.1-fold. Capillary depletion experiments showed that 
CBSA-PO was distributed into the brain parenchyma in a time-dependent manner, with few 
polymersomes detected, indicating that conjugation of polymersomes with CBSA significantly 
improved their transcytosis across the brain–blood barrier.
Conclusion: These results suggest that CBSA-PO is a promising drug brain delivery carrier 
with low toxicity.
Keywords: brain delivery kinetics, biodegradable polymersomes, cationic albumin, brain–blood 
barrier
Introduction
The delivery of therapeutic agents to treat diseases of the brain is far from efficient 
due to the blood–brain barrier, which separates blood from the underlying brain cells, 
protects neurons, and preserves homeostasis in the central nervous system.1,2 It has 
been shown that nearly 100% of large-molecule drugs and .98% of small-molecule 
drugs do not cross the blood–brain barrier. Consequently, the prognosis for many 
neurological disorders remains poor, and targeting drug delivery to the brain is a thera-
peutic   challenge. A great deal of effort is presently focused on developing strategies 
to deliver active drugs to the brain effectively. Recently, nanocarrier systems,3 such as 
micelles, liposomes, nanoparticles, and dendrimers,4 have been under   investigation as 
potential agents for drug delivery to the brain. Like most drugs, nanocarriers show low 
permeability at the blood–brain barrier. Thus, targeting ligands, such as transferrin,5 
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angiopep peptide,4 apolipoprotein,6 rabies virus glycopro-
tein peptide,7 and phage display peptide,8 have been used to 
modify the surface of nanocarriers to increase the efficiency 
of uptake by the brain. However, there remain issues of uptake 
efficiency, especially in the brain parenchyma. Therefore, 
novel nanocarriers rationally functionalized with targeting 
ligands are still necessary for the construction of effective 
brain-targeted delivery systems.
Polymersomes are a new class of vesicles self-assembled 
from amphiphilic block copolymers, which are currently 
attracting great interest because of their structural   similarity 
to living organelles and potential applications as nanosized 
reactors or drug delivery systems.9–12 The last decade has 
shown polymersomes to be promising alternatives to lipo-
somes, due to their remarkable, attractive, and feasible 
characteristics, including stealthiness, improved stability, 
and ease of functionalization.12–14 In addition, desirable 
and intelligent polymersomes can be designed to com-
bine multiple features required for drug delivery, such as 
biodegradability,15 targeting capability,16 and responsiveness 
to biologically relevant stimuli,17 such as pH, temperature, 
light, and reductive environments. Therefore, polymersomes 
are good candidates for drug delivery, and are currently 
being developed by many research groups. However, the 
vast majority of present efforts are focused on fabrication of 
novel functional polymersomes, whereas in vivo exploita-
tion of biodegradable polymersomes as brain drug delivery 
systems has not often been investigated.
Our group has reported a novel brain delivery system 
using poly(ethylene) glycol-poly(ε-caprolactone)   (PEG-PCL) 
polymersomes conjugated with the mouse-antirat mono-
clonal antibody, OX26,18 which can undergo endogenous 
receptor-mediated transcytosis across the blood–brain barrier. 
However, as a surface-conjugated targeting agent, OX26 
has many disadvantages, including an inability to bind to 
the human transferrin receptor, as well as the difficulty in 
preparing humanized antibodies and the potential risk of 
disturbing iron homeostasis in the brain,19 which greatly 
limit the application of OX26 in drug delivery to the brain. 
Cationic bovine serum albumin (CBSA) has been shown to 
have a greater binding capacity for brain microvessels and an 
increased accumulation profile in the brain via an absorptive-
mediated transcytosis pathway, indicating that CBSA might 
be a potential brain targeting vector despite its nonspecificity 
and immunogenicity.20,21 In our previous work, PEG-poly-
L-lactide nanoparticles conjugated with CBSA proved to 
be promising brain delivery carriers for small-molecule 
and large-molecule drugs, including peptides and genes.22,23 
In addition, CBSA was easier to prepare than the monoclonal 
antibody. Having these properties, CBSA was identified to 
be a promising alternative brain targeting vector.
Although many researchers have reported increased brain 
delivery of nanocarriers functionalized with targeting ligands, 
little is known about nanocarrier distribution in the brain 
parenchyma after transport across the blood-brain barrier. 
Nanocarrier content in the total brain includes nanocarriers 
that cross the blood–brain barrier and those that bind to or 
are endocytosed by endothelial cells without transcytosis into 
the post-capillary compartment. Identification of   nanocarriers 
in the brain parenchyma and cerebral endothelium could 
provide direct evidence of nanocarrier transport across the 
blood–brain barrier and an indepth insight into the kinetics of 
the process. Therefore, the present study evaluated the brain 
delivery kinetics of a polymersome-based molecular “Trojan 
horse”, whereby CBSA was conjugated to the surfaces of 
polymersomes (CBSA-PO). Biodegradable PEG-PCL was 
used to prepare the polymersomes by nanoprecipitation. 
The morphology, particle size, and surface characteristics 
of CBSA-PO were characterized by transmission electron 
microscopy, dynamic light scattering, and x-ray photoelectron 
spectroscopy. The cellular uptake and pharmacokinetics of 
CBSA-PO were investigated using coumarin-6 as a fluores-
cent probe, and the brain delivery kinetics of CBSA-PO were 
characterized using a well established capillary depletion 
technique.24,25 Cell viability assays was performed to confirm 
the safety and biodegradability of CBSA-PO.
Materials and methods
Materials and animals
Two diblock copolymers, MPEG3K-PCL15.8K and 
  maleimide-PEG3.4K-PCL16K, were synthesized by 
ring-opening polymerization of ε-CL, using MPEG 
  (molecular weight 3000 Da, NOF Corporation, Tokyo, 
Japan) and maleimide-PEG (molecular weight 3400 Da, 
Nektar   Therapeutics, San Francisco, CA), as described 
elsewhere.18 Traut’s reagent (2-iminothiolane) was pur-
chased from   Sigma-Aldrich (Saint Louis, MO). Coumarin-6 
and   coumarin-7 were obtained from Sigma-Aldrich, and 
Ellmann’s reagent (5,5-dithiobis-2-nitrobenzoic acid) was 
obtained from Acros Organics (Geel, Belgium). Bovine 
serum albumin (BP0042, Roche Applied Science, Basel, 
Switzerland) was used to prepare the CBSA, as in our 
previous work.26 Isoelectric focusing of CBSA showed 
that the pI of CBSA was about 8.5, and sodium dodecyl 
sulfate polyacrylamide gel electrophoresis determined that 
the molecular weight of CBSA was approximately 66 kDa. 
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A bEnd.3 cell line was obtained from the American Type 
Culture Collection (Rockville, MD). Fetal bovine serum 
and a related cell culture medium were purchased from 
Invitrogen (Gibco, Carlsbad, CA). Plastic cell culture dishes, 
plates, and flasks were ordered from Corning Incorporation 
(Lowell, MA). Double-distilled water was purified using a 
Millipore Simplicity System (Millipore, Bedford, MA). All 
other chemicals were of analytical reagent grade and were 
used without further purification.
Sprague-Dawley rats weighing 200–230 g were obtained 
from the Shanghai SLAC Laboratory Animal Co, Ltd 
  (Shanghai, China). The animals used for the experiments 
were treated according to protocols evaluated and approved 
by the ethics committee of Fudan University.
Preparation of cationic albumin-
conjugated polymersomes
Biodegradable polymersomes conjugated  
with cationic albumin
Biodegradable polymersomes were made using a blend of 
MPEG-PCL and maleimide-PEG-PCL by   nanoprecipitation.11 
Briefly, 20 mg of MPEG-PCL and 2 mg of maleimide-PEG-
PCL were dissolved in 1.0 mL of tetrahydrofuran. The poly-
mer solution was then injected slowly into 10 mL of 0.01 M 
phosphate-buffered saline (pH 7.4). Mild stirring was per-
formed to induce self-assembly. After 30 minutes, the solu-
tion was dialyzed against 0.01 M phosphate-buffered saline 
(pH 7.4) to remove the tetrahydrofuran. The polymersome 
solutions were concentrated using TM Ultra-4 (Amicon, 
Billerica, MA) concentrator tubes with ultrafilter membranes 
(molecular weight cut-off, 10 kDa). CBSA was thiolated and 
characterized as in our previous work.27 Thiolated CBSA was 
then incubated with the concentrated polymersomes with a 
thiol group to maleimide group molar ratio of 1:3 for 8 hours. 
The resulting CBSA-PO was purified by passage through a 
Sepharose CL-4B column eluted with 0.01 M phosphate-
buffered saline (pH 7.4). Preparation of the polymersomes 
loaded with coumarin-6 was the same as that used for the 
blank CBSA-PO, except that approximately 120 µg of 
coumarin-6 was added to the copolymer solution.
Morphology, particle size, and surface analysis
The shape and size of the unloaded polymersomes were 
observed by transmission electron microscopy   (JEM-1230, 
JEOL, Tokyo, Japan) following negative staining with 1% 
uranyl acetate solution. The mean diameter and zeta potential 
of the CBSA-PO were determined by dynamic light scatter-
ing using a zeta potential/particle sizer (Nicomp™ 380 ZLS, 
Particle Sizing Systems, Santa Barbara, CA). Surface CBSA 
densities were determined using the bicinchoninic acid 
protein assay combined with turbidimetry, as   previously 
described.18 The surface chemical composition of the 
polymersomes, CBSA-PO, and a mixture of maleimide-
PEG-PCL:MPEG-PCL (1:10) were analyzed by x-ray 
photoelectron spectroscopy on an RBD-upgraded PHI-
5000C ESCA system (Perkin Elmer, Boston, MA) as in 
our previous work.27
Drug-loading efficiency and in vitro  
release of coumarin-6 from CBSA-PO
The drug-loading efficiency of coumarin-6 in CBSA-PO 
was determined by high-performance liquid chromatography 
combined with turbidimetry.27 In vitro release of coumarin-6 
from CBSA-PO was performed in phosphate-buffered saline 
(pH 4 or 7.4) and in rat plasma.18 The samples released 
were analyzed by high-performance liquid chromatography 
(Agilent 1200, Santa Clara, CA) with a fluorescence detec-
tor at an excitation wavelength of 465 nm and an emission 
wavelength of 502 nm.27 Samples were shielded from light 
throughout the experimental procedure.
Quantitative determination of cell uptake  
by coumarin-6 loaded polymersomes
The bEnd.3 cells were seeded onto a 24-well plate at a 
density of 105 per well and incubated at 37°C for 24 hours. 
After a 30-minute incubation in Dulbecco’s modified Eagle’s 
medium (DMEM), the cells were treated with 100 µg/mL 
of coumarin-6-loaded CBSA-PO or polymersomes and 
  various inhibitors for 60 minutes, ie, DMEM (control), 
CBSA (1 mg/mL), poly-L-lysine (500 µg/mL), 0.1% (w/w) 
sodium azide, 450 mmol/L sucrose, 20 µmol/L phenylar-
sine oxide (PheASO), or 10 µg/mL filipin. After washing 
with ice-cold phosphate-buffered saline and acid buffer 
(120 mmol/L NaCl, 20 mmol/L sodium barbital, 20 mmol/L 
sodium acetate [pH 3]) at 4°C for 5 minutes, the cells 
were solubilized with 0.4 mL of 1% Triton X-100 at 4°C 
  overnight. Afterwards, 25 µL of the cell lysate from each 
well was sampled to determine the total cell protein content 
using a bicinchoninic acid protein assay kit. The rest of the 
cell lysate was used for extraction and high-performance 
liquid chromatography determination of coumarin-6.27 
A standard curve was constructed for the polymersomes by 
suspending them at different concentrations (5–200 µg/mL) 
in 1% Triton X-100, followed by the same extraction and 
high-performance liquid chromatography determination 
procedure as that used for the samples. Polymersome uptake 
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is expressed as percent uptake of the control. To evaluate the 
effect of temperature on cell uptake, the cells were treated 
according to the same procedure as described above, except 
that the cells were incubated for one hour with 100 µg/mL 
coumarin-6-loaded CBSA-PO or polymersomes at 4°C 
and 37°C, respectively. The uptake index was expressed as 
polymersomes (µg)/cellular protein (mg).
In vitro cytotoxicity of CBSA-PO
The bEnd.3 cells were seeded into a 96-well plate at a density 
of 104 per well and incubated for 24 hours before exposure to 
CBSA, polymersomes, and CBSA-PO samples in DMEM, in 
a series of concentrations for an additional 4 hours at 37°C. 
Eight wells treated only with DMEM were prepared as 
  controls. After exposure, the cytotoxicity of these formula-
tions was assayed using the MTT method.28 These experi-
ments were performed in quadruplicate.
Pharmacokinetics and brain delivery 
kinetics of CBSA-PO
Pharmacokinetic experiments
Pharmacokinetic experiments were performed as previously 
described.18 Briefly, rats were anesthetized intraperitone-
ally with 400 mg of chloral hydrate per kg of body weight. 
  Coumarin-6-labeled CBSA-PO, polymersomes, or CBSA-PO 
plus free CBSA (10 mg/kg) was injected into the left femoral 
vein at a dose of 10 mg/kg. Blood samples were collected via 
a cannula implanted in the left femoral artery at 0.25, 1, 2, 5, 
15, 30, 60, and 120 minutes following intravenous   injection. 
The blood volume was replaced with an equal volume of 
saline. At 120 minutes, the animals were decapitated, and 
the brain and other major organs, including the liver, spleen, 
heart, lung, and kidney, were collected, followed by a rapid 
wash with cold saline to remove any superficial blood. An 
additional incision was made into the heart to squeeze any 
remaining blood out of the ventricles.
Capillary depletion
The transport kinetics of CBSA-PO across the blood–brain 
barrier in vivo were investigated using a capillary deple-
tion technique, as described elsewhere.24,25 This technique 
separates the brain homogenate into the vascular pellet 
compartment and the postvascular supernatant compartment, 
which represents polymersomes bound to or endocytosed 
into endothelial cells and those transcytosed into the brain 
  interstitial space, respectively. In brief, Sprague Dawley 
rats were randomized into three groups and   administered 
coumarin-6-labeled CBSA-PO, polymersomes, or CBSA-
PO plus free CBSA (10 mg/kg) at a polymersome dose 
of 10 mg/kg via the tail vein. At hours 0.5, 1, 2, and 4, the 
rats were decapitated and blood samples were collected. 
  Subsequently, the brains were rapidly removed, weighed, and 
homogenized in 7 mL of cold 13% dextran solution. After 
centrifugation at 3000 g for 15 minutes at 4°C, a 5 mL ali-
quot of the homogenate was separated into the postvascular 
supernatant and the vascular pellet. Both fractions, as well as 
the whole homogenate, were carefully sampled for extraction 
and high-performance liquid chromatography determination 
of coumarin-6 as described below.
Analytical procedure
The tissue samples were homogenized on ice with three-fold 
volumes of deionized water, followed by addition of 10 µL of 
7-coumarin (internal standard, 50 ng/mL). The samples were 
extracted with 2 mL of n-hexane after 2 minutes of intense 
vortexing. After centrifugation at 12,000 rpm for 10 minutes, 
the supernatant was transferred and evaporated under a gentle 
stream of nitrogen at 40°C. The residue was dissolved in 
500 µL of mobile phase, and 20 µL was injected into the 
high-performance liquid chromatography system. The blood 
plasma samples, postvascular supernatants (0.5 mL), vascular 
pellets (0.2 g), and whole brain homogenate (0.5 mL) were 
treated in the same manner, without addition of water.
The chromatographic analysis was performed using a 
high-performance liquid chromatography system (Shimadzu 
Scientific Instruments Inc, Tokyo, Japan), including a pump 
(Model LC-10AT) and a fluorescence detector (Model 
RF-10AXL; λex = 465 nm, λem = 502 nm). Using methanol/
H2O (96:4, v/v) as the mobile phase, at a flow rate of 1.2 mL 
per minute, chromatographic separations were achieved 
using a C18 analytical column (5 µm, 4.6 × 200 mm, Dikma 
Diamonsil RP18 column) equipped with a guard column 
(Nova-Pak, Waters, Milford, MA) at 35°C.
Data analysis
The concentration of polymersomes in blood and tissues 
(including the homogenate, vascular pellet, and postvas-
cular supernatant) were expressed as % ID/mL (% ID, 
percentage of injected dose) or % ID/g. Using nonlinear 
regression, the plasma data were fitted to a biexponential 
equation,  At A e A e k t k t ()=+
− −
1 2
1 2 , where A(t) is % ID per 
mL of   plasma.29 Pharmacokinetic parameters, such as 
plasma clearance and steady-state volume of distribution 
(Vss), were calculated from A1, A2, k1, and k2. Area under 
the blood concentration curve (AUC0–t) was calculated 
by noncompartmental data analysis of blood concentra-
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tions. The volume of distribution (Vd) in the brain after 
intravenous injection was determined from the ratio of the 
amount of drug in brain   tissue (% ID per g tissue) divided 
by the concentration of drug (% ID/mL) in terminal plasma. 
The brain permeability surface area (PS) product was 
determined as follows:30
 
PS
VC pT
Cp td t
d
t =
−V0 []
∫
()
()
0
where Cp(T) was the terminal blood concentration and V0 was 
the brain polymersome distribution volume.   According 
to the method reported by Huwyler et al and Lu et al,30,31 
V0 was determined as the amount of polymersomes in 
brain   tissue (% ID per g tissue) 2 minutes after intravenous 
injection divided by the plasma concentration of polymer-
somes (% ID/mL) at the same time point as that described 
  previously.18 Brain uptake was expressed as % ID per g of 
tissue and calculated as: % ID/g(t) = PS × AUC0–t.
Results
Characterization of cationic albumin-
conjugated polymersomes
Morphology, particle size, and zeta potential
Transmission electron microscopy (Figure 1) showed 
that CBSA-PO spontaneously assembled by a blend of 
MPEG3K-PCL7.6K and maleimide-PEG3.4K-PCL7K 
had a relatively narrow size distribution and that conjuga-
tion with CBSA did not change their vesicle-like shape. 
Dynamic light scattering showed that the average diameter 
of the polymersomes was around 95 nm (Table 1). A slight 
increase in vesicle size was observed for CBSA-PO, which 
had an average diameter of around 101 nm. There was no 
significant difference in vesicle size between unloaded 
CBSA-PO and CBSA-PO loaded with coumarin-6, indicat-
ing that the incorporation of coumarin-6 did not influence 
vesicle size.
The Zeta potential values for polymersomes, CBSA-PO, 
and coumarin-6-loaded CBSA-PO in 0.001 M NaCl solution 
(pH 7.0) are shown in Table 1. Compared with the poly-
mersomes, the zeta potential value of CBSA-PO increased 
dramatically, from -20 mV to around +9 mV , indicating that 
CBSA conjugation caused inversion of the zeta potential. No 
significant difference in zeta potential was observed between 
CBSA-PO loaded with coumarin-6 and unloaded CBSA-PO, 
indicating that incorporation of coumarin-6 did not influence 
the zeta potential.
Surface analysis
The mean number of CBSA molecules per polymersome 
on the surface of the CBSA-PO was 95.8 ± 9.2, which has 
been shown in other studies to be a reasonable density for 
brain targeting.31 Quantitative data for the surface chemical 
composition of maleimide-PEG-PCL:MPEG-PCL (1:10) 
copolymers, polymersomes, and CBSA-PO were provided 
by the x-ray photoelectron spectroscopy analysis (Table 2). 
Surface nitrogen was only detected in the CBSA-PO 
sample, and the existence of CBSA incorporated onto the 
polymersome surface was determined from the N1s x-ray 
photoelectron spectrum (Figure 2D). Decomposition of the 
C1s envelope revealed the presence of four types of carbon 
(Figure 2). Their relative composition ratios, based on area, 
are shown in Table 2. Because peak 2, at a binding energy 
of 286.6 eV , was regarded as an indicator of MPEG,32 the 
presence of a PEG corona layer on the polymersome surface 
could be confirmed by the increased C–O–C peak ratio of 
30.8% for polymersomes and 33.6% for CBSA-PO, in com-
parison with 18.7% for the maleimide-PEG-PCL:MPEG-
PCL copolymer mixture.
Figure 1 Transmission electron microscopy images of cationic albumin-conjugated 
biodegradable polymersomes negatively stained with 1% uranyl acetate solution 
(bar 100 nm).
Table 1   Particle  sizes  and  zeta  potential  values  of  PO  and 
CBSA-PO, loaded or not loaded with coumarin-6 (n = 3)
Vesicle Mean size,  
nm
Zeta potential   
(mV)a
PO 95.2 ± 4.3 -19.2 ± 0.8
CBSA-PO 101.1 ± 7.6 9.3 ± 0.5
Coumarin-6-loaded PO 96.6 ± 5.2 -20.3 ± 0.7
Coumarin-6-loaded CBSA-PO 102.7 ± 5.5 9.5 ± 0.3
Note: aMeasured in NaCl solution (10-3 M). 
Abbreviations: PO, polymersomes;  CBSA, cationic bovine serum albumin.
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Figure 2 Carbon C1s envelopes from X-ray photoelectron spectroscopy analysis of 
(A) mixture of maleimide-PEG-PCL:MPEG-PCL (1:10) copolymers, (B) PO without 
CBSA attached, and (C) CBSA-PO (maleimide-PEG-PCL:MPEG-PCL, 1:10 ratio). 
(D) Nitrogen N1s envelopes from x-ray photoelectron spectroscopic analysis of 
CBSA-PO. 
Abbreviations: PO, polymersomes; PEG, poly(ethylene glycol); CBSA, cationic bovine 
serum albumin; PCL, poly(ε-caprolactone); MPEG, methoxy poly(ethylene glycol).
Table 2 X-ray photoelectron spectroscopy of maleimide-PEG-PCL:MPEG-PCL mixture (1:10), PO-coupled with or without CBSA
Samples XPS elemental ratio (%) XPS C1s envelope ratios (%) XPS O1s envelope   
ratios (%) C O N C–C/C–H C–O–C C–O–C=O O–C=O
O=C O–C
Binding energy (eV)
285.0 286.6 287.3 289.4 533.5 534.4
Copolymers 75.1 24.9 *   7.5 18.7 56.6 17.2 34.7 65.3
PO 74.2 25.8 * 27.4 30.8 27.3 14.5 44 56
CBSA-PO 74.1 25.5 0.4 13.5 33.6 33.1 19.8 37.7 62.3
Notes: *Below the detection limit. Copolymers are maleimide-PEG-PCL:MPEG-PCL mixture (1:10). 
Abbreviations: XPS, x-ray photoelectron spectroscopy; PO, polymersomes; PEG, poly(ethylene glycol); PCL, poly(ε-caprolactone); CBSA, cationic bovine serum albumin; 
MPEG, methoxy poly(ethylene glycol).
Drug-loading efficiency and in vitro release  
of coumarin-6 from CBSA-PO
The drug-loading efficiency of coumarin-6 loaded CBSA-PO 
was 0.8%, which is high enough for qualitative and quan-
titative study in vitro and in vivo.31,33 In vitro release tests 
showed that, after a 48-hour incubation period, approximately 
0.50%, 0.39%, and 2.58% of coumarin-6 was released from 
CBSA-PO in pH 4.0 phosphate-buffered saline, pH 7.4 
phosphate-buffered saline, and rat plasma, respectively. This 
lack of release indicates that the fluorescence signal detected 
in the blood and organ samples could be attributed mainly to 
the coumarin-6 encapsulated within the polymersomes and 
that coumarin-6 could be an accurate probe for polymersome 
behavior in vivo.
Cellular uptake of polymersomes
bEnd.3 cells are an immortalized mouse brain endothelial 
cell line with specific endothelial properties, blood–brain 
  barrier characteristics, and amenability to numerous 
  molecular   interventions. These cells were chosen as a simple 
blood–brain barrier model to study the intracellular delivery 
mechanism of CBSA-PO in vitro.34,35 Polymersome uptake 
by bEnd. 3 cells was found to be temperature-dependent, 
and the uptake index for both CBSA-PO and polymersomes 
at 37°C was much higher than that at 4°C (P , 0.01). CBSA 
conjugation with the polymersomes significantly increased 
the cell uptake by 1.6-fold compared with that of noncon-
jugated polymersomes at 37°C (Figure 3A). The effects of 
different inhibitors on polymersome uptake are shown in 
Figure 3B and C. Energy depletion by sodium azide signifi-
cantly decreased the intracellular uptake of both CBSA-PO 
and polymersomes, indicating that polymersome uptake 
was energy-dependent. PheASO and hypertonic sucrose, 
which are inhibitors of endocytosis, also greatly decreased 
uptake of polymersomes. In addition, the uptake of CBSA-
PO was strongly inhibited in the presence of free polyca-
tions, such as CBSA and poly-L-lysine, while the uptake of 
polymersomes was not affected. Furthermore, filipin, which 
is a specific inhibitor of caveolae-associated endocytosis, 
significantly decreased the uptake of CBSA-PO but not 
that of polymersomes. All of these results suggest that the 
uptake of CBSA-PO was subject to absorptive-mediated 
endocytosis, and that caveolae were involved in the endo-
cytosis process.
In vitro cytotoxicity of CBSA-PO
As shown in Figure 4, free CBSA was toxic at high con-
centrations, while CBSA-PO and polymersomes had little 
toxicity against bEND.3 cells. Even at the highest concen-
tration (8 mg/mL), cell viability for the CBSA-PO group 
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at the highest   concentration (8 mg/mL) of CBSA-PO, the 
CBSA concentration in the solution was only 0.28 mg/mL, 
a low concentration demonstrating little toxicity against 
bEnd.3 cells.
Pharmacokinetics and brain delivery  
of coumarin-6 loaded CBSA-PO
To investigate delivery of CBSA-PO to the brain, pharma-
cokinetic experiments were performed in Sprague Dawley 
rats following intravenous injection of coumarin-6 labeled 
CBSA-PO at a dosage of 10 mg/kg. Disappearance of CBSA-
PO from the blood circulation compartment occurred in a 
biexponential manner (Figure 5). The plasma clearance, area 
under the plasma concentration curve at steady-state (AUCss), 
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and   polymersome group was above 85%, and there were 
no significant differences in cell viability in comparison 
with the control. No significant differences in cell viability 
were observed between the polymersome and CBSA-PO 
groups. These results confirmed the good safety of biode-
gradable CBSA-PO. The difference in cell viability between 
CBSA-PO and CBSA might be related to the CBSA con-
centrations in the solution. For CBSA-PO, assuming that 
the mean number of CBSA molecules per polymersome 
on the surface of CBSA-PO was 95.8 ± 9.2, the CBSA 
content amounted to about 3.5% (w/w), which was a very 
small proportion of the total amount of CBSA-PO. Even 
CBSA-PO
CBSA-PO + free CBSA
PO
100
10
%
 
I
D
/
m
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0 0.5 12 1.52 .5
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Figure 5 Blood polymersome concentration (% ID/mL) versus time after intravenous 
injection of 10 mg/kg of PO, CBSA-PO, and CBSA-PO plus 10 mg/kg of free CBSA.
Note: Data are presented as the mean ± standard deviation of n = 4 rats/point. 
Abbreviations:  PO,  polymersomes;  CBSA,  cationic  bovine  serum  albumin; 
ID, the injected dose.
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and mean residence time were calculated from the data in 
Figure 5 and are presented in Table 3. All the polymersomes 
had long circulation times; however, polymersomes conju-
gated with CBSA showed an increase in plasma clearance 
and a decrease in mean residence time compared with non-
conjugated polymersomes (Figure 5 and Table 3). Although 
the AUC0–t for CBSA-PO was only 59% that of the poly-
mersomes, the brain permeability surface area product for 
CBSA-PO was 3.6-fold that of the polymersomes (Figure 6). 
The average % ID/g brain tissue for CBSA-PO at 2 hours 
was 0.11%, which was increased by 2.1-fold compared with 
polymersomes, suggesting that CBSA-PO might be a promis-
ing carrier for drug delivery to the brain.
Brain delivery kinetics of coumarin-6 
loaded CBSA-PO
Capillary depletion experiments showed that the polymer-
somes distributed into the rat brain in a time-dependent 
  manner. As shown in Figure 6, the concentration of CBSA-PO 
in the total brain (the homogenate) that reached the highest 
value at one hour was significantly higher than that of the poly-
mersomes at 0.5, 1, 2, and 4 hours after injection. However, 
total brain uptake of CBSA-PO was significantly decreased 
by coinjection of free CBSA. These results are in agreement 
with those of the pharmacokinetic study.   Polymersome con-
centrations for the CBSA-PO group in the vascular pellet 
compartment were significantly higher in comparison with 
those for the polymersome group, but decreased on coinjec-
tion of free CBSA (Figure 6B), demonstrating a much higher 
rate of binding and internalization of CBSA-PO into the brain 
vasculature in vivo as compared with nonconjugated polymer-
somes. The polymersome concentration in the postvascular 
supernatant, which represents the polymersomes entering the 
brain parenchyma, was very low at all time points, ranging 
between 0.01% ID/g and 0.04% ID/g. Compared with the 
polymersome group, the polymersome concentration in the 
CBSA-PO group was much higher, reaching   approximately 
0.15% ID/g at one hour (Figure 6C). The AUC0–t in the 
Table 3 Steady-state area under the plasma concentration-time curve and plasma clearance of different formulations labeled with 
coumarin-6
Group AUCss (% ID*h/mL) Cl (mL/h/kg) MRT (hours) PS (μL/h/g tissue) % ID/g tissue
PO 2.94 ± 0.52 154 ± 24 1.47 ± 0.34 23.8 ± 2.7 0.052 ± 0.013
CBSA-PO 1.37 ± 0.42** 343 ± 83** 0.82 ± 0.25* 86.3 ± 8.6** 0.111 ± 0.015**
CBSA-PO + CBSA 2.20 ± 0.34*,† 205 ± 30*,† 0.96 ± 0.36 37.5 ± 5.8*,†† 0.075 ± 0.019*,†
Notes: Data are the mean ± standard deviation, n = 4. Statistically significant differences by Student’s t-test when compared with the corresponding value of control: 
*P , 0.05; **P , 0.01 versus PO; †P , 0.05; ††P , 0.01 versus CBSA-PO. 
Abbreviations: AUCss, steady-state area under the concentration time curve; Cl, clearance; MRT, mean residence time; PO, polymersomes; PS, permeability surface area 
product; CBSA, cationic bovine serum albumin.
postvascular supernatant for the CBSA-PO group was 5.3-fold 
that for the polymersome group, indicating that the polymer-
somes conjugated with CBSA had significantly improved 
transcytosis across the blood–brain barrier. As with the total 
brain uptake of polymersomes, coinjection of free CBSA and 
CBSA-PO significantly decreased accumulation of CBSA-PO 
in the brain parenchyma. In addition, the ratio of the CBSA-
PO concentration in the postvascular supernatant to that of 
the vascular pellet increased from 0.8 to 2.7 between 0.5 and 
4 hours post injection, while that of the polymersomes did 
not change significantly (Figure 6D), which provides direct 
evidence of the CBSA-PO transcytosis process across the 
blood–brain barrier.
Discussion
This study elucidates the brain delivery kinetics of poly-
mersomes after conjugation with CBSA. It is shown 
that polymersomes distribute into the rat brain in a time-
dependent manner and conjugation of polymersomes with 
CBSA significantly improves their transcytosis across the 
blood–brain barrier. The polymersome concentrations in 
the postvascular supernatant (representing the brain paren-
chyma) in the CBSA-PO group are 2.3–8.8-fold those of 
the polymersome group after intravenous injection, indi-
cating that the parenchymal concentration of CBSA-PO 
was higher than that of nonconjugated polymersomes at 
all time points. In addition, the AUC0–t in the postvascular 
supernatant for the CBSA-PO group was 5.3-fold that of the 
polymersome group.   Moreover, the ratio of the CBSA-PO 
concentration in the postvascular supernatant to that of the 
vascular pellet increased dramatically with time, while that 
of the polymersomes did not change significantly, which 
provides direct evidence of CBSA-PO transport across the 
blood–brain barrier.   Furthermore, one hour after injection, 
the CBSA-PO concentration in the postvascular supernatant 
was approximately 68% of that in the total homogenate, 
indicating high efficiency of CBSA-PO transcytosis through 
the blood–brain barrier.
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Graphic  abstract  Brain  delivery  kinetics  of  cationic  bovine  serum  albumin- 
conjugated biodegradable polymersomes.
Abbreviation: BBB, blood–brain barrier.
In this study, CBSA-PO proved to be an efficient brain 
drug delivery system in vitro and in vivo, which might be 
attributable to the optimal chemical and physical properties 
of the polymersomes, including their size, surface charge, 
and surface chemistry. Moderate CBSA density on the poly-
mersomes improved the blood–brain barrier   permeability 
to polymersomes, but showed moderate blood clearance. 
In a previous report, we showed that a higher density of CBSA 
on PEGylated nanoparticles increased not only blood–brain 
barrier permeability to nanoparticles but also clearance of 
these nanoparticles from the blood, and that a moderate CBSA 
density on nanoparticles (109.9 per n  anoparticle) was optimal 
for brain delivery.31 In the present study, the mean number 
of CBSA molecules per polymersome on the surface of 
CBSA-PO was 95.8 ± 9.2, which is close to the optimal 
CBSA density on nanocarriers. Our in vitro study showed 
that uptake of polymersomes by bEnd.3 cells was significantly 
increased (by 1.6-fold) after surface conjugation with CBSA. 
Further in vivo biodistribution experiments demonstrated 
that use of CBSA-conjugated polymersomes significantly 
increased the brain permeability surface area value (by 3.6-
fold) while the AUC only decreased to 59%. According to the 
equation, % ID/gt(t) = PS × AUC0−t, uptake of CBSA-PO by 
the brain at 2 hours increased by 2.1-fold that of the uptake 
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for polymersomes. A high PEG density on the surface of the 
polymersomes afforded good resistance to opsonization and 
extended vesicle circulation times.12 X-ray photoelectron 
spectroscopy confirmed that a corona layer with a high PEG 
density (30.8%) existed on the polymersome surface, which 
was higher than for PEGylated nanoparticles (21.7%).27 
In vivo biodistribution studies demonstrated that biodegrad-
able polymersomes had longer circulation times compared 
with PEGylated nanoparticles.31 Although CBSA conjugation 
increased the zeta potential of polymersomes from -20 mV to 
around +9 mV , which might increase clearance of polymer-
somes from the blood,36 this value still agrees well (within 
10 mV) with the optimal zeta potential for in vivo delivery 
of nanocarriers.37 Finally, maintaining a vesicle size around 
100 nm might be optimal for improving the pharmacokinetics 
of polymersomes38 and advantageous for endocytosis by brain 
capillary endothelial cells.30,39
There are three negatively charged barriers at the blood–
brain barrier.40 At systemic physiological pH, the luminal 
and abluminal surfaces of brain capillary endothelial cells 
have an overall negative charge, and the basement membrane 
contiguous to the basolateral side of the brain capillary 
endothelial cells is also a negatively charged barrier, due to 
its chondroitin-rich and heparin sulfate-rich glycosaminogly-
cans components.40 All three of these successive electrostatic 
barriers create an environment for selective transport of 
cationic substances from the blood to the brain. The lumi-
nal side provides anionic sites for interacting with cationic 
substances and inducing absorptive-mediated endocytosis. 
The anionic properties of both the abluminal cell side and 
the basement membrane can facilitate externalization of cat-
ionic substances from the lumen to the brain interstitium.40 
It has been shown that cationic albumin not only binds to 
the surfaces of brain capillary endothelial cells but also 
increases the uptake of proteins and nanoparticles conjugated 
with cationic albumin by the brain via absorptive-mediated 
transcytosis.20,22 In the present study, CBSA was conjugated 
with biodegradable polymersomes, and the brain uptake 
mechanism of CBSA-PO was investigated. Similar to the 
brain delivery of other cationic substances via absorptive-
mediated transcytosis, the cellular uptake of CBSA-PO was 
energy-dependent because energy depletion and/or a low 
temperature greatly reduced uptake of polymersomes and 
CBSA-PO by the cells. Inhibitors of endocytosis, such as 
PheASO and hypertonic sucrose, also greatly decreased the 
uptake of polymersomes, indicating that the polymersomes 
were internalized by the cells via endocytosis. In addition, 
free polycations, such as CBSA and poly-L-lysine, strongly 
inhibited cellular uptake of CBSA-PO but not of polymer-
somes. Further in vivo brain delivery results revealed that 
coadministration of CBSA and CBSA-PO significantly 
decreased the blood-brain barrier permeability to CBSA-PO 
as well as its uptake by the brain. These results suggested that 
uptake of CBSA-PO by the brain was subject to absorptive-
mediated transcytosis. Clathrin-coated pits or caveolae might 
be involved in transcytosis at the blood–brain barrier. The 
uptake of Syn-B peptides, a family of cationic cell-pene-
trating peptides, starts with the caveolae-independent path-
way.41 For natural polyamines, two endocytic pathways have 
been described in various cultured cells.42,43 In this study, 
filipin, which is a specific inhibitor of caveolae-associated 
endocytosis, significantly decreased the uptake of CBSA-
PO but not of polymersomes, suggesting that caveolae are 
involved in the endocytosis of CBSA-PO. However, whether 
clathrin-coated pits are involved in transcytosis and which 
anion component at the blood–brain barrier plays a critical 
role in cellular internalization of CBSA-PO are still in need 
of verification and more pharmacological inhibitors might 
need to be used to elucidate the endocytosis mechanism of 
polymersomes more clearly.
Conclusion
A novel brain drug delivery system, based on biodegrad-
able PEG-PCL polymersomes conjugated with CBSA, was 
established for the first time to the authors’ knowledge. 
Coupling of CBSA with polymersomes was confirmed 
by X-ray photoelectron spectroscopy. It was shown that 
uptake of CBSA-PO by bEnd.3 cells was energy-driven 
and absorptive-mediated. Pharmacokinetic and brain dis-
tribution results demonstrated that polymersomes had long 
circulation times, and CBSA conjugation on polymersomes 
significantly increased the blood–brain barrier permeability 
surface area product and percentage of injected dose per 
gram of brain. Moreover, capillary depletion experiments 
showed that CBSA-PO distributed to the brain parenchyma 
in a time-dependent manner and CBSA conjugation with 
polymersomes significantly improved their transcytosis 
across the blood–brain barrier. Cell viability assays con-
firmed good safety of CBSA-PO for delivery to the brain. 
These results suggest that CBSA-PO is a promising brain 
delivery carrier with low toxicity.
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